Urinary [TIMP-2] × [IGFBP7] and serum procalcitonin to predict and assess the risk for short-term outcomes in septic and non-septic critically ill patients.

Acute kidney injury Intensive care unit Procalcitonin Sepsis [TIMP-2] × [IGFBP7]

Journal

Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873

Informations de publication

Date de publication:
21 Apr 2020
Historique:
received: 23 09 2019
accepted: 13 04 2020
entrez: 23 4 2020
pubmed: 23 4 2020
medline: 23 4 2020
Statut: epublish

Résumé

Biomarkers can play a critical role by facilitating diagnosis and stratification of disease, as well as assessment or prediction of disease severity. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 product ([TIMP-2] × [IGFBP7]) predict the development and progression of AKI and recently procalcitonin (PCT), a widely used biomarker for sepsis diagnosis and management, has been associated with AKI occurrence in ICU patients. To assess combinations of [TIMP-2] × [IGFBP7] and PCT results for prediction and risk stratification of short-term outcomes in septic and non-septic patients, a retrospective cohort analysis of critically ill patients was performed in a multidisciplinary ICU. ROC curve analysis was used in order to evaluate predictive performance of combined results of [TIMP-2] × [IGFBP7] and PCT at the time of admission for AKI development. To verify the utility of adding [TIMP-2] × [IGFBP7] and PCT results for risk assessment, we evaluated the predictive value of having a single-marker positivity compared to a double-marker positivity using the widely used cut-off of 0.3 (ng/mL) 433 patients were analysed, of whom 168 had AKI within 48 h (93 septic and 65 non-septic patients). Combination of [TIMP-2] × [IGFBP7] and PCT showed a good predictive ability for AKI occurrence (AUC 0.81, 95% CI 0.77-0.86, p < 0.001, Sens 78%, Spec 73%). Combinations of biomarkers increased the odd ratios (OR) considerably. A single-marker positivity showed a fourfold risk increase, while the double-marker positivity a 26-fold risk increase for AKI occurrence. Moreover, the double-marker positivity showed an elevated risk for AKD at 7 days in non-septic patients (OR 15.9, 95% CI 3,21-73,57, p < 0.001) and for mortality within 7 days in septic patients (HR 4.1, 95% CI 1.4-11.8, p = 0.001). Although combining the results of [TIMP-2] × [IGFBP7] and PCT may be a useful tool to identify and stratify ICU patients at high risk for septic AKI and short-term adverse outcomes, data should be confirmed in a large prospective study.

Sections du résumé

BACKGROUND BACKGROUND
Biomarkers can play a critical role by facilitating diagnosis and stratification of disease, as well as assessment or prediction of disease severity. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 product ([TIMP-2] × [IGFBP7]) predict the development and progression of AKI and recently procalcitonin (PCT), a widely used biomarker for sepsis diagnosis and management, has been associated with AKI occurrence in ICU patients. To assess combinations of [TIMP-2] × [IGFBP7] and PCT results for prediction and risk stratification of short-term outcomes in septic and non-septic patients, a retrospective cohort analysis of critically ill patients was performed in a multidisciplinary ICU. ROC curve analysis was used in order to evaluate predictive performance of combined results of [TIMP-2] × [IGFBP7] and PCT at the time of admission for AKI development. To verify the utility of adding [TIMP-2] × [IGFBP7] and PCT results for risk assessment, we evaluated the predictive value of having a single-marker positivity compared to a double-marker positivity using the widely used cut-off of 0.3 (ng/mL)
RESULTS RESULTS
433 patients were analysed, of whom 168 had AKI within 48 h (93 septic and 65 non-septic patients). Combination of [TIMP-2] × [IGFBP7] and PCT showed a good predictive ability for AKI occurrence (AUC 0.81, 95% CI 0.77-0.86, p < 0.001, Sens 78%, Spec 73%). Combinations of biomarkers increased the odd ratios (OR) considerably. A single-marker positivity showed a fourfold risk increase, while the double-marker positivity a 26-fold risk increase for AKI occurrence. Moreover, the double-marker positivity showed an elevated risk for AKD at 7 days in non-septic patients (OR 15.9, 95% CI 3,21-73,57, p < 0.001) and for mortality within 7 days in septic patients (HR 4.1, 95% CI 1.4-11.8, p = 0.001).
CONCLUSIONS CONCLUSIONS
Although combining the results of [TIMP-2] × [IGFBP7] and PCT may be a useful tool to identify and stratify ICU patients at high risk for septic AKI and short-term adverse outcomes, data should be confirmed in a large prospective study.

Identifiants

pubmed: 32318859
doi: 10.1186/s13613-020-00665-9
pii: 10.1186/s13613-020-00665-9
pmc: PMC7174532
doi:

Types de publication

Journal Article

Langues

eng

Pagination

46

Références

Crit Care. 2013 Feb 06;17(1):R25
pubmed: 23388612
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Crit Care Med. 2019 Oct;47(10):e820-e826
pubmed: 31343478
Crit Care Med. 2006 Jul;34(7):1996-2003
pubmed: 16715031
Contrib Nephrol. 2018;193:100-112
pubmed: 29393129
Blood Purif. 2019;47(1-3):140-148
pubmed: 30336490
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Semin Nephrol. 2015 Jan;35(1):12-22
pubmed: 25795496
J Infect Chemother. 2015 Apr;21(4):257-63
pubmed: 25677555
Kidney Int. 2013 Sep;84(3):457-67
pubmed: 23636171
Res Vet Sci. 2012 Oct;93(2):921-7
pubmed: 22001598
Nephrol Dial Transplant. 2016 Jan;31(1):16-22
pubmed: 26044835
Med Intensiva. 2018 Oct;42(7):399-408
pubmed: 29433841
Crit Care. 2016 Mar 15;20:69
pubmed: 26983854
Biostatistics. 2000 Jun;1(2):123-40
pubmed: 12933515
Crit Care. 2018 Jul 4;22(1):168
pubmed: 29973233
Am J Respir Crit Care Med. 2014 Apr 15;189(8):932-9
pubmed: 24559465
Nat Rev Nephrol. 2018 Oct;14(10):607-625
pubmed: 30135570
Kidney Int. 2015 Jan;87(1):62-73
pubmed: 25317932
Nephrology (Carlton). 2018 Dec;23(12):1090-1095
pubmed: 28967168
Angiology. 2015 Nov;66(10):957-63
pubmed: 25688117
Crit Care. 2018 Aug 3;22(1):188
pubmed: 30075798
Surg Infect (Larchmt). 2018 Feb/Mar;19(2):131-136
pubmed: 29356604
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Sci Rep. 2019 Mar 18;9(1):4777
pubmed: 30886220
Crit Care Med. 2016 Oct;44(10):1851-60
pubmed: 27355527
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Crit Care Med. 2006 Oct;34(10):2596-602
pubmed: 16915118
Headache. 2014 Mar;54(3):472-84
pubmed: 24512072
Nephrol Dial Transplant. 2014 Nov;29(11):2054-61
pubmed: 25237065
Crit Care. 2017 Mar 25;21(1):77
pubmed: 28340605
Crit Care Med. 2000 Feb;28(2):458-61
pubmed: 10708183

Auteurs

Ilaria Godi (I)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy. ilaria.g88@libero.it.
Department of Medicine-DIMED, Section of Anesthesiology and Intensive Care Medicine, University of Padova, Padua, Italy. ilaria.g88@libero.it.

Silvia De Rosa (S)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.
Department of Anesthesiology and Intensive Care Medicine, San Bortolo Hospital, Vicenza, Italy.

Francesca Martino (F)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.
Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy.

Simona Bazzano (S)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.
Department of Anesthesiology and Intensive Care, Azienda Ospedalieriero-Universitaria Maggiore DELLA Carità, Novara, Italy.

Marina Martin (M)

Department of Anesthesiology and Intensive Care Medicine, San Bortolo Hospital, Vicenza, Italy.

Elisa Boni (E)

Department of Anesthesiology and Intensive Care Medicine, San Bortolo Hospital, Vicenza, Italy.

Maria Rosa Carta (MR)

Department of Laboratory Medicine, San Bortolo Hospital, Vicenza, Italy.

Claudia Tamayo Diaz (C)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.

Gaia Mari (G)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.

Anna Lorenzin (A)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.

Massimo de Cal (M)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.

Valentina Corradi (V)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.

Carlotta Caprara (C)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.

Davide Giavarina (D)

Department of Laboratory Medicine, San Bortolo Hospital, Vicenza, Italy.

Claudio Ronco (C)

International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy.
Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy.

Classifications MeSH